Sumitomo Pharma Co. Ltd (SMDPY PINK) stock market data APIs
$9.9063
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
Sumitomo Pharma Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Sumitomo Pharma Co., Ltd. engages in manufacture, purchase, and sale of pharmaceutical products for medical treatment in Japan, North America, and Asia. The company offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. It also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, the company offers veterinary drugs, medical devices, etc. It has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Prev. Close
9.9063
Open
9.9063
High
9.9063
Low
9.9063
52 wk Range
1.99-10
Market Cap
4 550 M
P/E Ratio
25
Shares Outstanding
397 M
Revenue
416 159 M
EPS
0.1952
Beta
0.552
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sumitomo Pharma Co. Ltd data using free add-ons & libraries
Get Sumitomo Pharma Co. Ltd Fundamental Data
Sumitomo Pharma Co. Ltd Fundamental data includes:
- Net Revenue: 416 159 M
- EBITDA: 61 013 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-29
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sumitomo Pharma Co. Ltd News
New
Central Bank, Tech Outlooks Lift Asian Stock Markets
Asian stock markets rallied on Wednesday after fresh record highs overnight on Wall Street, and on r PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
US Jobs, Federal Reserve Outlooks Lift Asian Stock Markets
Asian stock markets gained ground on Friday after recent soft US jobs market reports bolstered outlo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Sumitomo Pharma Co., Ltd. reports FQ1 results
* Sumitomo Pharma Co., Ltd. press release [https://www.sumitomo-pharma.com/news/assets/pdf/eir20250731.pdf] (OTCPK:SMDPY [https://seekingalpha.com/symbol/SMDPY]): FQ1 Net profit attributable to own...
Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis
– Nuvisertib (TP-3654), an oral investigational highly selective PIM-1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – MARLBOROUGH, Mass., July 3...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
